Clinical Trials
20
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials
Real World Use of Tocilizumab Biosimilar studY
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Fresenius Kabi SwissBioSim GmbH
- Target Recruit Count
- 600
- Registration Number
- NCT06247722
- Locations
- 🇩🇪
Rheumatologische Schwerpunktpraxis Berlin, Berlin, Germany
🇩🇪Rheumapraxis Dr. Liebhaber Halle, Halle, Germany
🇩🇪Facharztpraxis für Innere Medizin Ludwigsfelde, Ludwigsfelde, Germany
A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- Drug: US-licensed Prolia (Amgen)
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Fresenius Kabi SwissBioSim GmbH
- Target Recruit Count
- 553
- Registration Number
- NCT04934072
- Locations
- 🇵🇱
Osteo-Medic sc dr diabetolog Katarzyna Wasilewska, Białystok, Podlaskie, Poland
🇵🇱Centrum Kliniczno Badawcze J Brzezicki B Górnikiewicz Brzezicka Lekarze, Elbląg, Warminsko-Mazurskie, Poland
🇵🇱Ambulatorium Sp z o.o. - Elblag, Elbląg, Zulawy, Poland
MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Fresenius Kabi SwissBioSim GmbH
- Target Recruit Count
- 604
- Registration Number
- NCT04512001
- Locations
- 🇧🇬
Medical Center Hipokrat 2000 OOD, Haskovo, Khaskovo, Bulgaria
🇧🇬MHAT "Lyulin" EAD, Sofia, Sofiya, Bulgaria
🇧🇬Military Medical Academy - Sofia, Sofia, Sofiya, Bulgaria
Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS
- Conditions
- Crohn DiseaseAnkylosing SpondylitisUlcerative ColitisPediatric Crohns DiseaseNon-infectious UveitisRheumatoid ArthritisPolyarticular Juvenile Idiopathic ArthritisPsoriatic ArthritisHidradenitis SuppurativaPlaque Psoriasis
- Interventions
- Drug: 40 mg MSB11022
- First Posted Date
- 2019-07-12
- Last Posted Date
- 2020-03-25
- Lead Sponsor
- Fresenius Kabi SwissBioSim GmbH
- Target Recruit Count
- 216
- Registration Number
- NCT04018599
- Locations
- 🇺🇸
PRA Health Sciences (PRA) - Early Development Services (EDS), Lenexa, Kansas, United States
🇺🇸PRA-EDS, Salt Lake City, Utah, United States
Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Fresenius Kabi SwissBioSim GmbH
- Target Recruit Count
- 696
- Registration Number
- NCT03282851
- Locations
- 🇳🇿
Research site, Christchurch, New Zealand
- Prev
- 1
- 2
- Next